← Back to Search

Ketone Supplement

Exogenous Ketone Monoester for Type 2 Diabetes

N/A
Waitlist Available
Led By Jonathan Little, PhD
Research Sponsored by University of British Columbia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Have a type 2 diabetes diagnosis from a physician
Have stable use of glucose-lowering medications for at least 3 months
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1 through to day 10
Awards & highlights

Study Summary

This trial is testing whether ketone supplements can lower blood sugar and impact how the body's cells function.

Eligible Conditions
  • Type 2 Diabetes

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1 through to day 10
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1 through to day 10 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Glucose
Secondary outcome measures
Blood beta-hydroxybutyrate
Blood pressure
Body weight
+24 more
Other outcome measures
Cravings
Hunger and fullness cravings questionnaire
Supplement acceptability
+1 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: ExperimentalExperimental Treatment1 Intervention
Participants will consume 15 g of an active oral exogenous ketone monoester supplement 15 minutes prior to each meal of the day for a 14-day period. Pre-intervention (baseline) and post-intervention measurements will be obtained before and immediately after the 14-day period. All meals will be provided throughout the supplementation period Participants will wear a continuous glucose monitor for the first 10 consecutive days during the supplementation period.
Group II: PlaceboPlacebo Group1 Intervention
Participants will consume a flavor-matched placebo drink and undergo the same procedures described in the Experimental Arm
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Exogenous Ketone Monoester
2022
N/A
~20

Find a Location

Who is running the clinical trial?

University of British ColumbiaLead Sponsor
1,407 Previous Clinical Trials
1,766,534 Total Patients Enrolled
Jonathan Little, PhDPrincipal InvestigatorUniversity of British Columbia- Okanagan
3 Previous Clinical Trials
190 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~5 spots leftby Mar 2025